AstraZeneca stock price forecast: GBX13,613 resistance as AZN trades flat

Traders Union
All News
Financial News
AstraZeneca slips 0.09% to GBX13,222

Highlights

Choppy markets have driven renewed interest in AstraZeneca as investors seek stability in defensive healthcare stocks.
Ongoing volatility has limited downside for AstraZeneca, but the stock remains pressured by broad market selling.
AstraZeneca trades below key moving averages with technicals signaling dominant seller pressure, a likely GBX11,593–14,850 range, and only a 26% probability of an upward move near term.

Defensive demand rises as volatility sustains pressure on AstraZeneca

Choppy trading sessions have renewed investor attention on the traditionally defensive qualities of healthcare stocks such as AstraZeneca, which is among the largest UK-listed pharmaceutical companies by market presence, according to Kalkinemedia. Increased demand for defensive stocks often emerges during periods of heightened volatility as investors seek stability and predictable cash flows. While this dynamic may have limited further downside in the stock, price action has remained under broader selling pressure.

Bearish signals persist as technical barriers align with faded momentum

On the H1 timeframe, AZN is trading below its MA-20 at GBX13,327 and MA-50 at GBX13,337, while the daily chart places it under the long-term MA-200 at GBX13,613. The Ichimoku Kijun level on the daily stands as resistance at GBX14,121. Momentum signals are mixed: MACD indicates ongoing selling momentum, while ADX suggests some underlying buyer support. The RSI reads 43.62 (Sell), CCI also signals Sell, and BBP is oversold—evidence of seller dominance intraday, despite the Stoch RSI flashing a potential buy. The Awesome Oscillator (AO) adds further confirmation of a negative short-term trend.

Downside risk prevails as consolidation likely within broad trading band

Looking ahead, the expected trading range for AZN over the next two to three days is GBX11,593 to GBX14,850, representing a typical volatility band relative to current levels. The baseline scenario is for price consolidation within this corridor, with a 26% probability of an upward move and a 74% probability of further downside. A bullish scenario would require a breakout above immediate resistance at the Kijun level, while a bearish move could be triggered by a breach of the lower boundary of the projected range.

Anton Kharitonov, expert at Traders Union, notes that AstraZeneca remains under technical pressure despite renewed defensive demand. He sees persistent selling signals and resistance levels capping any immediate recovery. The probability continues to favor further downside barring a breakout above GBX14,121. "Unless key resistance is reclaimed, I remain defensive and expect price consolidation or additional weakness in the short term."

Earlier, analysts noted that AstraZeneca shares continued to face prevailing selling pressure despite positive pipeline and regulatory developments. The current outlook reinforces this cautious stance, highlighting that traders should monitor the projected lower boundary around GBX11,593 for signs of further downside risk in the near term.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.